Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7476144 | 0.79 | NOS1 (0.39) | NOS1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6098722 | 0.79 | CA2 (0.45) | NOS1CA1CA2CA4CA5A | |
| SCHEMBL23569112 | 0.79 | NOS1 (0.39) | NOS1RAB9ASMN1; SMN2 | |
| SCHEMBL16486114 | 0.77 | TSHR (0.35) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL8346166 | 0.77 | TSHR (0.35) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL23569833 | 0.76 | NOS1 (0.41) | NOS1CA1CA2CA4CA5A | |
| SCHEMBL15281026 | 0.74 | GLP1R (0.35) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL16511460 | 0.74 | TSHR (0.33) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL9872420 | 0.71 | CA2 (0.56) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL11703741 | 0.69 | RARA (0.48) | KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120058893-A1 | HERBICIDALLY ACTIVE KETOSULTAMS AND DIKETOPYRIDINES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120058893-A1 | HERBICIDALLY ACTIVE KETOSULTAMS AND DIKETOPYRIDINES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | US | disclosed |
| EP-1757635-B1 | Curable ink comprising modified oxetane compound | FUJIFILM CORP (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-6358983-B1 | FOR THERAPY OF HYPERTENSION, ACUTE MYOCARDIAL INFARCT, PULMONARY HYPERTENSION, RAYNAUD'S SYNDROME, CEREBRAL VASOSPASMS, STROKE, BENIGN PROSTATE HYPERTROPHY, ATHEROSCLEROSIS, ASTHMA AND PROSTATE CANCER | ABBOTT LABORATORIES | 2002-03-19 | — | — | US | disclosed |
| CN-1278805-A | Novel heterocycle-substituted alpha-hydroxycarboxylic acid derivatives, their production and their use as endothelin receptor antagonists | BASF AG (DE) | 2001-01-03 | — | — | CN | disclosed |
| EP-1037883-A1 | NOVEL HETEROCYCLICALLY SUBSTITUTED $g(a)-HYDROXYCARBOXLIC ACID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999025701-A1 | NOVEL HETEROCYCLICALLY SUBSTITUTED α-HYDROXYCARBOXLIC ACID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058893-A1 | HERBICIDALLY ACTIVE KETOSULTAMS AND DIKETOPYRIDINES | KHK, KCNA1, KCNA2 | NOS1 2188/4885CA1 2807/4885CA2 1268/4885 |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | NOS1 4527/4885CA1 4676/4885CA2 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.